{
  "id": 6298366,
  "title": "ProBioGen Grants Transgene Additional License for AGE1.CR.pIX Cell Line",
  "url": "https://urgent.news/2026/09/08/probiogen-grants-transgene-additional-license-for-age1-cr-pix-cell",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-08T16:20:49.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/bioprocessing/probiogen-grants-transgene-additional-license-for-age1-cr-pix-cell-line/"
  },
  "original_language": "en",
  "account": "ProBioGen and Transgene have extended their existing collaboration by granting Transgene an additional license for ProBioGen's suspension AGE1.CR.pIX R cell line. This specialized production technology is designed to enhance Transgene's manufacturing capabilities for viral vaccine production.\n\nThe cell line is a stable proliferating avian cell derived from primary cells of a duck embryo. Developed as an alternative to chicken eggs, it serves as a cost-effective solution for large-scale vaccine production. The product is available in both suspension and adherent forms and has been optimized for viral vaccine production and stability.\n\nTransgene CEO Alessandro Rive expressed confidence in the technology's potential for future clinical needs, while ProBioGen's CSO, Volker Sandig, noted the importance of a continuous cell line qualified as a GMP master cell bank. This qualification ensures every batch begins from the same fully characterized starting material, providing consistency across production batches.\n\nTransgene specializes in designing and developing targeted immunotherapies for cancer treatment. Their clinical-stage programs include a portfolio of viral vector-based immunotherapeutics, with TG4050 as their lead asset in adjuvant treatment for head and neck cancers. TG4070, another candidate derived from their myvac platform, is in Phase I clinical development for non-small lung cancer in combination with nivolumab. Other viral vector-based assets under Transgene's portfolio include BT-001, an oncolytic virus in clinical development.",
  "summary": "ProBioGen’s AGE1.CR.pIX is a stable proliferating avian cell line derived from duck embryo primary cells. It was developed as an alternative to the use of chicken eggs for large-scale vaccine production. The post ProBioGen Grants Transgene Additional License for AGE1.CR.pIX Cell Line appeared first on GEN - Genetic Engineering and Biotechnology News .",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}